Is CSL a fallen ASX giant to buy in July?

CSL Ltd (ASX: CSL) is one of Australia’s greatest corporate success stories.

For decades, the biotech company has built a global business around specialised medical products that solve serious healthcare problems. It has expanded internationally, developed valuable expertise, and become one of the country’s most recognised companies.

But great companies can still go through difficult periods.

Confidence lost

CSL has lost some of the market confidence it once enjoyed, with investors questioning growth expectations, execution, and whether the company can return to its previous level of performance.

The question for investors is whether this is a permanent change or an opportunity created by short-term disappointment.

I think CSL shares are worth buying in July.

A biotech business built on real needs

The reason I continue to like CSL is that its products are connected to genuine medical demand.

The company operates across plasma-derived therapies, vaccines, and specialist healthcare products. These are areas where patients and healthcare systems rely on effective treatments rather than temporary consumer trends.

That creates a different type of growth opportunity.

Healthcare demand tends to be supported by long-term forces such as ageing populations, improving access to treatment, and advances in medical technology.

CSL’s plasma business remains particularly important. Collecting plasma, manufacturing therapies, and supplying patients around the world requires significant infrastructure, expertise, and regulatory capability.

Those advantages have taken decades to build.

I think that is easy to overlook when investors are focused on short-term earnings pressure.

The market has become more cautious

CSL’s recent challenges are real. Investors have raised concerns around the performance of parts of the business, including Vifor, while also assessing the longer-term outlook for vaccines and plasma therapies.

Those concerns deserve attention. However, I think the market may have moved too far in the other direction.

CSL does not need to return to being viewed as a perfect growth company for its shares to perform well. It just needs to stabilise the business, improve execution, and show that its core strengths remain valuable.

That feels achievable to me.

One thing I like about CSL is that it operates in complex markets where experience is important. Competitors cannot simply appear overnight and replicate decades of research, manufacturing capability, regulatory knowledge, and global relationships.

Why this could be an opportunity

When a company with a strong history falls out of favour, investors often have to decide whether the problems are temporary or structural.

With CSL, I think it is a temporary issue and the long-term opportunity remains intact.

The company still operates in markets with significant unmet demand. It still has global scale. And it still has the expertise required to compete in highly specialised healthcare areas.

The recovery may take time. Investors may need patience while management continues improving the business and rebuilding confidence. The share price may not immediately reflect any progress, but I would argue the worst is now behind it.

Foolish takeaway

I think CSL is a fallen ASX giant worth buying in July.

The company has faced genuine challenges, and investors should not ignore them. But I think the strength of CSL’s underlying business, its global position, and the long-term demand for its products make it one of the more interesting recovery opportunities on the ASX.

Sometimes the best investments come from companies that have temporarily lost favour while their long-term advantages remain.

The post Is CSL a fallen ASX giant to buy in July? appeared first on The Motley Fool Australia.

More reading

• The only 3 ASX blue-chip shares I’d buy and hold until 2036
• July is historically one of the best months for ASX shares. Can July FY27 deliver?
• How to tell if an ASX share is cheap or a value trap
• 2 ASX healthcare shares crashing, now bouncing: buy, hold or sell?
• ASX healthcare shares have jumped 21% since June. Can the recovery continue?

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.